Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

ОБЗОР ОСНОВНЫХ ПОЛОЖЕНИЙ КОНСЕНСУСА III РАБОЧЕЙ ИТАЛЬЯНСКОЙ ГРУППЫ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ H.PYLORI-ИНФЕКЦИИ

Полный текст:

Аннотация

Цель обзора. Изложить основные положения консенсуса III Рабочей итальянской группы по диагностике и лечению H.pylori-инфекции. Результатом работы III Рабочей группы явилось уточнение некоторых положений IV Маастрихтского консенсуса, а, именно, характера взаимосвязи H.pylori с гастроэзофагеальной рефлюксной болезнью, функциональной диспепсией, НПВП/аспириновой гастропатией, внежелудочными заболеваниями, детализирована область применения инвазивных и неинвазивных методов исследования, обновлены алгоритмы терапии H.pylori-инфекции в условиях роста антибиотикорезистентности. Углублено понимание роли эрадикации H.pylori в профилактике рака желудка.

Об авторах

А. М. Осадчук
Государственное бюджетное образовательное учреждение высшего профессионального образования «Самарский государственный медицинский университет» Министерства здравоохранения РФ
Россия


И. Л. Давыдкин
Государственное бюджетное образовательное учреждение высшего профессионального образования «Самарский государственный медицинский университет» Министерства здравоохранения РФ
Россия


Т. А. Гриценко
Государственное бюджетное образовательное учреждение высшего профессионального образования «Самарский государственный медицинский университет» Министерства здравоохранения РФ
Россия


Список литературы

1. Zagari R. M., Romano M., Ojetti V., et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015 // Digestive and Liver Disease. - 2015. - Vol. 47. - Р. 903 - 912.

2. Malfertheiner P., Megraud F., O’Morain C. A., et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report // Gut. - 2012. - Vol. 61. - Р. 646 - 64.

3. Gisbert J. P., Calvet X. Helicobacter pylori test and treat strategy for managementof dyspepsia: a comprehensive review // Clinical and Translational Gastroenterology. - 2013. - Vol. 28. - e32.

4. Eusebi L. H., Zagari R. M., Bazzoli F. Epidemiology of Helicobacter pylori infection // Helicobacter. - 2014. - Vol. 19 (Suppl. 1). - Р. 1 - 5.

5. Zagari R. M., Law G. R., Fuccio L., et al. Epidemiology of functional dyspepsia andsubgroups in the Italian general population: an endoscopic study //Gastroenterology. - 2010. - Vol. 138. - Р. 1302 - 11.

6. Mana F., Vandebosch S., Miendje Deyi V., et al. Prevalence of and risk factors for H.pylori infection in healthy children and young adults in Belgium anno 2010/2011 // Acta Gastroenterol Belg. - 2013. - Vol. 76. - Р. 381 - 5.

7. Rossi S., Crocetti E., Capocaccia R., et al. Estimated of cancer burden in Italy //Tumori. - 2013. - Vol. 99. - Р. 416 - 24.

8. Zagari R. M., Fuccio L., Bazzoli F. Investigating dyspepsia // BMJ 2008. - 337a: 1400.

9. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: whatare we treating?: Comment on «Helicobacter pylori eradication in functionaldyspepsia» // Archives of Internal Medicine. - 2011. - Vol. 171. - Р. 1936 - 7.

10. Ronkainen J, Agréus L. Epidemiology of reflux symptoms and GORD // Best Practice & Research Clinical Gastroenterology. - 2013. - Vol. 27. - Р. 325 - 37.

11. Lee Y. C., Chen T. H., Chiu H. M., et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention // Gut. - 2013. - Vol. 62. - Р. 676 - 82.

12. Yaghoobi M., Farrokyar F., Yuan Y., et al. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis //American Journal of Gastroenterology. - 2010. - Vol. 105. - Р. 1007 - 13.

13. Qian B., Shijie M., Shang L., et al. Effect of HP eradication on gastroesophageal reflux disease //Helicobacter. - 2011. - Vol. 16. - Р. 255 - 65.

14. Fox J. G., Kuipers E. J. Long-term proton pump inhibitor administration, HP and gastric cancer: lessons from the gerbil // Gut. - 2011. - Vol. 60. - Р. 567 - 8.

15. Abraham N. S., Hlatky M. A., Antman E. M., et al. Expert Consensus Documenton the concomitant use of proton pump inhibitors and thienopyridines: afocused update of the ACCF/ACG/AHA 2008 expert consensus document onreducing the gastrointestinal risks of antiplatelet therapy and NSAID use: areport of the American College of Cardiology Foundation Task Force on ExpertConsensus Documents // Circulation. - 2010. - Vol. 122. - Р. 2619 - 33.

16. Levi M. M., Eerenberg E., Löwenberg E., et al. Bleeding in patients using new anti-coagulants or antiplatelet agents: risk factors and management //Netherlands Journal of Medicine. - 2010. - Vol. 68. - Р. 68 - 76.

17. Qu X. H., Huang X. L., Xiong P., et al. Does Helicobacter pylori infection play a role iniron deficiency anemia? A meta-analysis // World Journal of Gastroenterology. - 2010. - Vol. 16. - Р. 886 - 96.

18. Goddard A. F., James M. W., McIntyre A. S., et al. Guidelines for the management of iron deficiency anaemia // Gut. - 2011. - Vol. 60. - Р. 1309 - 16.

19. Huang X., Qu X., Yan W., et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori // Postgraduate Medical Journal. - 2010. - Vol. 86. - Р. 272 - 8.

20. Yuan W., Li Yumin, Yang Kehu, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials //Scandinavian Journal of Gastroenterology. - 2010. - Vol. 45. - Р. 665 - 76.

21. Annibale B., Capurso G., Lahner E., et al. Concomitant alterations in intra-gastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia // Gut. - 2003. - Vol. 52. - Р. 496 - 501.

22. Franchini M., Cruciani M., Mengoli C., et al. Effect of Helicobacter pylorieradication on platelet count in idiopathic thrombocytopenic purpura: a sys-tematic review and meta-analysis //Journal of Antimicrobial Chemotherapy. -2007. - Vol. 60. - Р. 237 - 46.

23. Stasi R., Sarpatwari A., Segal J. B., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review // Blood. - 2009. - Vol. 113. - Р. 1231 - 40.

24. Arnold D. M., Bernotas A., Nazi I., et al. Platelet count response to HP treatment in patients with immune thrombocytopenic purpura with and without HP infection: a systematic review //Haematologica. - 2009. - Vol. 94. - Р. 850 - 6.

25. Lahner E., Persechino S., Annibale B., et al. (Other than iron) and Helicobacter pylori infection: a systematic review // Helicobacter. - 2012. - Vol. 17. - Р. 1 - 15.

26. Wang Z. W., Yan L., Huang L. Y., et al. Helicobacter pylori infection contributesto high risk of ischemic stroke: evidence from a meta-analysis // Journal of Neurology. - 2012. - Vol. 259. - Р. 2527 - 33.

27. Gravina A. G., Federico A., Ruocco E., et al. Helicobacter pylori infection but notsmall intestinal bacterial overgrowth may play a pathogenic role in rosacea //United European Gastroenterology Journal. - 2015. - Vol. 3. - Р. 17 - 24.

28. Ferwana M, Abdulmajeed I, Alhajiahmed A, et al. Accuracy of urea breath testin Helicobacter pylori infection: meta-analysis // World Journal of Gastroenterology. - 2015. - Vol. 2. - Vol. 1305 - 14.

29. Gisbert J. P., De La M. F., Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of infection: a systematic review and meta-analysis //American Journal of Gastroenterology. - 2006. - Vol. 101. - Р. 1921 - 30.

30. Calvet X., Lario S., Ramirez-Lazaro M. J., et al. Accuracy of monoclonal stool tests for determining cure of Helicobacter pylori infection after treatment //Helicobacter. - 2010. - Vol. 15 (3). - Р. 201 - 05.

31. Vaira D., Gatta L., Ricci C., et al. Helicobacter pylori: diseases, tests and treatment //Digestive and Liver Disease. - 2001. - Vol. 33. - Р. 788 - 94.

32. Sanchez-Delgado J., Genè E., Suarez D., et al. Has HP prevalence in bleeding peptic ulcer been underestimated? A meta-regression //American Journal of Gastroenterology. - 2011. - Vol. 106. - Р. 398 - 405.

33. Ekstrom A. M., Held M., Hansonn L. E., et al. Helicobacter pylori in gastriccancer established by CagA immunoblot as a marker of past infection //Gastroenterology. - 2001. - Vol. 121. - Р. 784 - 91.

34. De Francesco V., Zullo A., Ierardi E., et al. Phenotypic and genotypic Helicobacterpylori clarithromycin resistance and therapeutic outcome: benefits and limits //Journal of Antimicrobial Chemotherapy. - 2010. - Vol. 65. - Р. 327 - 32.

35. Rimbara E., Noguchi N., Kawai T., et al. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the levelof resistance and identification of a resistance conferring mutation in GyrB //Helicobacter. - 2012. - Vol. 17. - Р. 36 - 42.

36. Cambau E., Allerheiligen V., Coulon C., et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacterpylori // Journal of Clinical Microbiology. - 2009. - Vol. 47. - Р. 3600 - 7.

37. De Francesco V., Zullo A., Giorgio F., et al. Change of point mutations in the H.pylori rRNA associated with clarithromycin resistance in Italy // Journal of Medical Microbiology. - 2014. - Vol. 63. - Р. 453 - 7.

38. Liu Q., Qi D., Kang J., et al. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection //European Journal of Gastroenterology and Hepatology. - 2015. - Vol. 27. - Р. 221 - 5.

39. Figura N., Crabtree J. E., Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori //Journal of Antimicrobial Chemotherapy. - 1997. - Vol. 39. - Р. 585 - 90.

40. Villoria A., Garcia P., Calvet X., et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication //Alimentary Pharmacology and Therapeutics. - 2008. - Vol. 28. - Р. 868 - 77.

41. Farup P. G., Lange O. J., Tholfsen J., et al. The effect of Helicobacter pylori retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends on the first-line therapy //Journal of Clinical Gastroenterology 2002. - Vol. 35. - Р. 379 - 82.

42. Almeida N., Romãozinho J. M., Donato M. M., et al. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study //Helicobacter 2014. - Vol. 19. - Р. 90 - 7.

43. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption // Gut. - 2013. - Vol. 62. - Vol. 34 - 42.

44. Yang Y., Ford A. C., Khan K. J., et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2013. Art No: CD370083.

45. Zullo A., Esposito G., Ridola L., et al. Prevalence of lesions detected atupper endoscopy: an Italian survey //European Journal of Internal Medicine. - 2014. - Vol. 25. - Р. 772 - 6.

46. Gatta L., Vakil N., Vaira D., et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy // BMJ. - 2013. - Vol. 347. - f4587.

47. Molina-Infante J., Romano M., Fernandez-Bermejo M., et al. Optimized non-bismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance // Gastroenterology. - 2013. - Vol. 145. - Р. 121 - 8.

48. Malfertheiner P., Bazzoli F., Delchier J., et al. Helicobacter pylori eradication witha capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: arandomised, open-label, non-inferiority, phase 3 trial, Pylera Study Group //Lancet. - 2011. - Vol. 377. - Р. 905 - 13.

49. Liou J. M., Lin J., Chang C. Y., et al. Levofloxacin-based and clarithromycin-basedtriple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with cross-over design // Gut. - 2010. - Vol. 59. - Р. 572 - 8.

50. Federico A., Gravina A. G., Miranda A., et al. Eradication of Helicobacter pylori infection: which regimen first? //World Journal of Gastroenterology. - 2014. - Vol. 20. - 665 - 72.

51. Di Caro S., Fini L., Daoud Y., et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second line: a systematic review // World Journal of Gastroenterology. - 2012. - Vol. 18. - Р. 5669 - 78.

52. Federico A., Nardone G., Gravina A. G., et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection //Gastroenterology. - 2012. - Vol. 143. - Р. 55 - 61.

53. Saracino I. M., Zullo A., Holton J., et al. High prevalence of primary antibioticresistance in Helicobacter pylori isolates in Italy // Journal of Gastrointestinal and Liver Diseases. - 2012. - Vol. 21. - Р. 363 - 5.

54. Chung J. W., Lee J. H., Yung H. Y., et al. Second-line Helicobacter pylori eradication: arandomized comparison of 1 week or 2 week bismuth-containing quadruple therapy // Helicobacter. - 2011. - Vol. 16. - Р. 289 - 94.

55. Rokkas T., Sechophulos P., Robotis I., et al. Cumulative HP eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen // American Journal of Gastroenterology. - 2009. - Vol. 104. - Р. 21 - 5.

56. Gisbert J. P., Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection //Alimentary Pharmacology and Therapeutics. - 2012. - Vol. 35. - Р. 209 - 21.

57. Fiorini G., Vakil N., Zullo A., et al. Culture-based selection therapy for patientswho did not respond to previous treatment for Helicobacter pylori infection // Clinical Gastroenterology and Hepatology. - 2013. - Vol. 11. - Р. 507 - 10.

58. Ruggero P. Use of probiotics in the fight against Helicobacter pylori //World Journal of Gastroenterology. - 2014. - Vol. 5. - Р. 384 - 91.

59. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccha-romyces boulardii supplementation on Helicobacter pylori eradication ratesandside effects during treatment // Alimentary Pharmacology and Therapeutics. - 2010. - Vol. 32. - Р. 1069 - 79.

60. Wang Z. H., Gao Q. Y., Fang J. Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic com-pound preparation in Helicobacter pylori eradication therapy // Journal of Clinical Gastroenterology. - 2013. - Vol. 47. - Р. 25 - 32.

61. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplemen-tation increases Helicobacter pylori eradication rate: evidence from a meta-analysis // Revista Espanola de Enfermedades Digestivas. - 2013. - Vol. 105. - Р. 445 - 53.

62. Zojaji H., Ghobakhlou M., Rajabalinia H., et al. The efficacy and safety of adding the probiotic Saccharomyces boulardii to standard triple therapy for eradication of HP: a randomized controlled trial // Gastroenterology and Hepatology from Bed to Bench. - 2013. - Vol. 6 (Suppl. 1). - S99-104.

63. Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection inclinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy //Helicobacter. - 2012. - Vol. 17. - Р. 254 - 63.

64. Ford A. C., Forman D., Hunt R. H., et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials //BMJ. - 2014. - Vol. 348. - g. 3174.

65. Wang H. L., Zhou P. Y., Liu P., et al. Role of p16 gene promotor methylation in gastric carcinogenesis: a meta-analysis // Molecular Biology Reports. - 2014. - Vol. 41. - Р. 4481 - 92.

66. Marcos-Pinto R., Dinis-Ribeiro M., Carneiro F., et al. First-degree relatives of early-onset gastric cancer patients show a high risk for gastric cancer: phenotype and genotype profile //Virchows Archiv. - 2013. - Vol. 463. - Р. 391 - 9.

67. McLean M. H., El-Omar E. M. Genetics of gastric cancer //Nature Reviews Gastroenterology & Hepatology. - 2014. - Vol. 11. - Р. 664 - 74.

68. Yan S., Li B., Bai Z. Z., et al. Clinical epidemiology of gastric cancer in Hehuang valley of China: a 10-year epidemiological study of gastric cancer //World Journal of Gastroenterology. - 2014. - Vol. 20 (30). - Р. 10486 - 94.

69. Dorji D., Dendup T., Malaty H. M., et al. JM. Epidemiology of Helicobacter pylori in Bhutan: the role of environment and geographic location // Helicobacter. - 2014. - Vol. 19. - Р. 69 - 73.

70. Tsukanov V. V., Butorin N. N., Maady A. S., et al. Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in Eastern Siberia // Helicobacter. - 2011. - Vol. 16. - Р. 107 - 12.

71. Rugge M., Correa P., Dixon M. F., et al. Gastric mucosa atrophy: inter-observer consistency using new criteria for classification and grading. Alimentary //Pharmacology and Therapeutics. - 2002. - Vol. 16. - Р. 1249 - 59.

72. Dinis-Ribeiro M., Areia M., de Vries A. C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG). European Society of Pathology, and the Sociedade Portoguesa de Endoscopia Digestiva (SPED) // Endoscopy. - 2012. - Vol. 44. - Р. 74 - 94.

73. Sanduleanu S., Jonkers D., de Bruine A., et al. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa // Alimentary Pharmacology and Therapeutics. - 2001. - Vol. 15. - Р. 379 - 88.

74. Fuccio L., Zagari R. M., Eusebi L. H., et al. Meta-analysis: can Helicobacter pylorieradication treatment reduce the risk for gastric cancer? //Annals of Internal Medicine. - 2009. - Vol. 151. - Р. 121 - 8.

75. Yamaji Y., Watabe H., Yoshida H., et al. High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors //Helicobacter. - 2009. - Vol. 14. - Р. 81 - 96.

76. Dinis-Ribeiro M., Yamaki G., Miki K., et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening // Journal of Medical Screening. - 2004. - Vol. 11. - Р. 141 - 7.

77. Rabitti S., Greenwood D., Eusebi L. H., et al. Sensitivity and specificity of thepanel test «Gastropanel» for the non invasive diagnosis of atrophic gastritis //Digestive and Liver Disease. - 2014. - Vol. 46 (Suppl. 2). - S90.

78. Sinning C., Schaefer N., Standop J., et al. Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment // European Journal of Surgical Oncology. - 2007. - Vol. 33. - Р. 2022 - 6.

79. Rokkas T., Sechopoulos P., Pistiolas P., et al. Helicobacter pylori infection and gastric histology in first degree relatives of gastric cancer patients: a meta-analysis //European Journal of Gastroenterology and Hepatology. - 2010. - Vol. 22. - Р. 1128 - 31.

80. Poulsen A. H., Christensen S., McLaughlin J. K., et al. Proton pump inhibitors and risk of gastric cancer: a population based cohort-study // British Journal of Cancer. - 2009. - Vol. 100. - Р. 1503 - 7.

81. Santibanez M., Alguacil I., Garcia De La Hera M., et al. Occupational exposures and risk of stomach cancer by histological type // Occupational and Environmental Medicine. - 2012. - Vol. 69. - Р. 268 - 75.

82. Dinis-Ribeiro M., Areia M., de Vries A. C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from theEuropean Society of Gastrointestinal Endoscopy (ESGE), European Heli-cobacter Study Group (EHSG). European Society of Pathology, and theSociedade Portoguesa de Endoscopia Digestiva (SPED) // Endoscopy. - 2012. - Vol. 44. - Р. 74 - 94.

83. Rugge M., Fassan M., Pizzi M., et al. Operative link for gastritis assessment vsoperative link on intestinal metaplasia assessment // World Journal of Gastroenterology. - 2011. - Vol. 17. - Р. 4596 - 601.

84. Ивашкин В. Т., Шептулин А. А., Лапина Т. Л. и соавт. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2012. - № 3. - С. 80 - 92.


Для цитирования:


Осадчук А.М., Давыдкин И.Л., Гриценко Т.А. ОБЗОР ОСНОВНЫХ ПОЛОЖЕНИЙ КОНСЕНСУСА III РАБОЧЕЙ ИТАЛЬЯНСКОЙ ГРУППЫ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ H.PYLORI-ИНФЕКЦИИ. Экспериментальная и клиническая гастроэнтерология. 2016;(5):33-44.

For citation:


Osadchuk A.M., Davydkin I.L., Gricenko T.A. OVERVIEW BASIC PROVISIONS CONSENSUS OF THE III WORKING ITALIAN GROUP FOR DIAGNOSIS AND TREATMENT OF H.PYLORI-INFECTION. Experimental and Clinical Gastroenterology. 2016;(5):33-44. (In Russ.)

Просмотров: 41


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)